Ainos, Inc. Warrants - AIMDW STOCK NEWS

Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced the issuance of two convertible promissory notes totaling US$3 million to investors. The notes, maturing in two years, bear an interest rate of 6% per annum and can be converted into common shares at US$1.50 each. The unsecured notes aim to strengthen the company's financial position and support its product pipeline. Ainos operates in point-of-care testing and innovative therapeutics, with a focus on low-dose interferon and COVID-19 diagnostics. This offering is exempt from certain U.S. securities registration requirements.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has signed a Memorandum of Understanding with Taiwanese drug manufacturer Tah-An Chemical & Pharmaceutical Co., Ltd. to explore the feasibility of manufacturing an animal investigational new drug using its VELDONA® formulation. The collaboration aims to begin animal clinical trials in Q1 2023. Ainos will provide technical assistance while Tah-An will handle manufacturing, leveraging its experience since 1966. This partnership is viewed as a significant step in Ainos' commercialization strategy, capitalizing on Tah-An's manufacturing expertise to enhance its product pipeline.

Ainos, Inc. (NASDAQ: AIMD, AIMDW) shared a letter from CEO Chun-Hsien Tsai, reflecting on 2022's challenges and outlining growth strategies for 2023. The company successfully uplisted to Nasdaq in August 2022, enhancing its capital access. Notable projects include Ainos Flora, a non-invasive STI testing device, and VELDONA®, an interferon alpha treatment. Ainos aims to expand its product pipeline, with ongoing clinical studies and potential applications in veterinary medicine. Financially, Ainos reduced its debt ratio significantly from 75% to 6.8% and reported cash of $2.4 million. The company intends to avoid shareholder dilution while pursuing growth opportunities.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced it is pursuing out-licensing opportunities for five new drug candidates of its low-dose oral interferon-alpha formulation, VELDONA. The candidates have successfully completed Phase 2 trials, with plans to accelerate them to Phase 3 and commercialization. The trials demonstrated VELDONA's effectiveness in treating various conditions, including Sjögren's syndrome and influenza. Ainos has invested nearly $40 million in the development of VELDONA and aims to enhance autoimmunity while minimizing side effects compared to high-dose injections.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced positive results from its preclinical efficacy study of VELDONA®, a low-dose oral interferon formulation, against the Omicron variant of SARS-CoV-2. The study demonstrated significant stabilization in lung inflammation and recovery in hamsters treated with VELDONA®. The results led to an application for Phase 2 clinical trials in patients with mild COVID-19. The treatment showed a better recovery trend, with no observed mixed-cellular inflammation in the VELDONA® group, compared to 50% in the placebo group.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA, aimed at treating mild COVID-19 symptoms. The trial will assess VELDONA's efficacy compared to standard care in a multicenter study in Taiwan. If successful, this could enhance treatments for COVID-19 and other viral infections.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. to test, manufacture, and package its VELDONA product candidates. This agreement aligns with Ainos' plans to submit an IND application for a Phase 2 study to the FDA by year-end. Additionally, Ainos is pursuing clinical trials for VELDONA against COVID-19 and has plans for further studies on thrombocytopenia and Sjögren's syndrome in 2023. This partnership aims to enhance Ainos' manufacturing capabilities and streamline its clinical trial preparations.

Ainos, a diversified medtech company, reported its second quarter financial results for 2022, showing a substantial revenue increase of 213.6% to US$636,627, driven by sales of COVID-19 Antigen Rapid Test Kits. Gross profit reached US$317,664, with a gross margin of 49.9%. However, total operating expenses surged 163.0% to US$2,261,960, impacting net loss, which increased to US$1,954,032. The company highlighted successful product developments, including an Emergency Use Authorization for its COVID-19 test kit in Taiwan, and progress on its VELDONA antiviral formulation.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced the closing of its public offering of 780,000 units at $4.25 per unit, yielding approximately $3.3 million in gross proceeds. Each unit includes one share of common stock and a warrant for one share. The stock underwent a reverse split at a 1-for-15 ratio, effective August 8, 2022. Additionally, the company granted underwriters a 45-day option to purchase an extra 117,000 shares and/or warrants. The offering was conducted under its SEC registration statement, effective as of August 8, 2022.